Bringing Advanced Therapies for Parkinson's Disease to the Clinic: An Analysis of Ethical Issues

Forskningsoutput: TidskriftsbidragÖversiktsartikelPeer review


Advanced therapies for Parkinson's disease (PD) constitute a broad range of treatments, each presenting specific ethical challenges. Some of these therapies are established and in clinical use, like device-aided therapies, and others, based on advanced therapeutic medicinal products (ATMPs), are still in early stage of clinical trials. This paper focuses on some common ethical issues arising in these two categories of advanced therapies, especially challenges arising when advanced therapies are proposed to PD patients in the form of advanced care, under a clinical trial, or, in case of ATMPs, under the 'hospital exemption' rule. The ethical issues covered here relate mainly to ensuring informed consent in these different contexts, to the stakeholder role of patient's non-professional caretakers, such as family, and to patient safety in treatments under 'hospital exemption'. To illustrate the points discussed in connection with 'hospital exemption' rule, the example of the EU has been chosen. This paper does not claim completeness of ethical issues raised by bringing advanced therapies for PD to the clinic, but rather presents examples of ethical challenges in this context.

Sidor (från-till)S147-S153
TidskriftJournal of Parkinson's Disease
StatusPublished - 2021

Bibliografisk information

Publisher Copyright:
© 2021 - The authors. Published by IOS Press.

Ämnesklassifikation (UKÄ)

  • Neurologi
  • Medicinsk etik


Utforska forskningsämnen för ”Bringing Advanced Therapies for Parkinson's Disease to the Clinic: An Analysis of Ethical Issues”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här